Original Research
Published on 05 Mar 2020
Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Content Validity
in Drugs Outcomes Research and Policies
Frontiers in Pharmacology
doi 10.3389/fphar.2020.00209
- 4,896 views
- 21 citations
